|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01931 IVD MEDICAL
Nominal 
1.730 +0.060 (+3.593%) | 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 3,162,415 | 2.397% | 3,088,387 | 2,748,809 | 2,730,670 | 2,428,210 |
| Cost of Sales | (2,411,242) | -0.225% | (2,416,686) | (2,140,668) | (2,164,402) | (1,952,045) |
| Gross Profit | 751,173 | 11.831% | 671,701 | 608,141 | 566,268 | 476,165 |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (9,468) | -54.108% | (20,631) | (11,455) | 13,918 | 4,542 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (18,829) | -16.903% | (22,659) | 2,795 | 8,335 | 577 | |
| Profit / (Loss) before Taxation | 401,777 | 18.403% | 339,329 | 283,789 | 267,940 | 231,956 | |
| Taxation | (135,743) | 32.817% | (102,203) | (88,259) | (106,190) | (77,338) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (5,614) | -- | 1,037 | 14,469 | 12,791 | 4,100 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 260,420 | 9.345% | 238,163 | 209,999 | 174,541 | 158,718 | |
| 2024/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 33,307 | 83.712% | 18,130 | 28,608 | 18,664 | 21,644 |
| Depreciation & Amortisation | 38,200 | 1.707% | 37,559 | 35,289 | 38,806 | 37,764 |
| Directors' Emoluments | -- | -- | 8,928 | 11,029 | 10,666 | 28,522 |
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/12 - Final | %Chg (Compare to Final) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 17.420 | -1.135% | 17.620 | 15.610 | 13.190 | 11.930 |
| DPS (cts) | 0.000 | -- | 8.325 | 7.251 | 6.602 | 4.431 |
| Dividend Payout Ratio (%) | -- | -- | 47.247% | 46.451% | 50.052% | 37.141% |
| Cash flow per share ($) | -- | -- | 0.216 | 0.186 | 0.123 | 0.128 |
| NBV per share ($) | 2.285 | -- | 2.469 | 2.328 | 2.202 | 2.155 |
| Remarks: | Real time quote last updated: 22/04/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 260,420 |
| %Change | 9.345% |
| EPS / (LPS) | RMB 0.174 |
| NBV Per Share (¥) | RMB 2.285 |